Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | PKM | P14618 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30279365 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1PKMMAPTLMNA | |
| SCHEMBL30279364 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1PKMMAPTLMNA | |
| SCHEMBL30279426 | 0.92 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1PKMMAPTLMNA | |
| SCHEMBL23978723 | 0.92 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1PKMMAPTLMNA | |
| SCHEMBL23978743 | 0.90 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1PKMMAPTLMNA | |
| SCHEMBL30279442 | 0.90 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1PKMMAPTLMNA | |
| SCHEMBL10129825 | 0.90 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1PKMMAPTLMNA | |
| SCHEMBL30279422 | 0.90 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1PKMMAPTLMNA | |
| SCHEMBL23978798 | 0.88 | P2RX7 (0.48) | SMN1; SMN2ALDH1A1MAPTLMNAP2RX7 | |
| SCHEMBL30279386 | 0.88 | P2RX7 (0.48) | SMN1; SMN2ALDH1A1MAPTLMNAP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| CN-115916176-A | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | 加利福尼亚大学董事会 | 2023-04-04 | — | — | CN | disclosed |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| WO-2021222789-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | SMN1; SMN2 3098/4885ALDH1A1 399/4885PKM 4776/4885 |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | ITGB1, ITGB2, ITGA2 | SMN1; SMN2 3098/4885ALDH1A1 399/4885PKM 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.